< Back to search
Filter
1

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

for
Higher-risk Myelodysplastic Syndrome
Location: Houston TX
Sponsor: Ascentage Pharma Group Inc.

Sex: All

Age: 18+

Code: NCT06641414

Phase3, Recruiting

Two Step Haplo With Radiation Conditioning

for
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia,
Location: Philadephia PA
Sponsor: Thomas Jefferson University

Sex: All

Age: 18+

Code: NCT05031897

Phase2, Recruiting

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

for
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes,
Location: New York NY, Hackensack NJ, Tampa FL, Nashville TN,
Sponsor: Orca Biosystems, Inc.

Sex: All

Age: 18+

Code: NCT07216443

Phase2, Recruiting

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

for
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: All

Age: 18 - 60

Code: NCT06315309

Phase2, Recruiting

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

for
Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML)
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06548230

Phase1, Phase2, Recruiting

Interested in new myelodysplastic syndromes trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

HEME Home Transfusion Program

for
Leukemia, Myeloma, Myelodysplastic Syndromes,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT06487247

Recruiting

Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

for
Clonal Cytopenia of Undetermined Significance,
Location: Aurora CO
Sponsor: University of Colorado, Denver

Sex: All

Age: 18+

Code: NCT07579429

Phase2, Recruiting

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

for
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 70

Code: NCT04708054

Phase2, Phase3, Recruiting

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

for
Acute Myeloid Leukemia, Graft Versus Host Disease,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70+

Code: NCT06996119

Phase1, Recruiting

Q702 for the Treatment of Patients With Hematologic Malignancies

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06712810

Phase1, Recruiting

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

for
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18 - 70+

Code: NCT06815003

Phase2, Recruiting

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

for
aGVHD, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia,
Location: Cleveland OH
Sponsor: Case Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT06904482

Phase2, Recruiting

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

for
High-risk Myelodysplastic Syndrome,
Location: Boston MA, New York NY, Philadelphia PA, Tampa FL,
Sponsor: Crossbow Therapeutics, Inc.

Sex: All

Age: 12+

Code: NCT06994676

Phase1, Recruiting

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

for
AML, MDS, Acute Leukemia, Acute Myeloid Leukemia,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 2 - 70+

Code: NCT07493538

Phase2, Recruiting

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

for
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome,
Location: Portland OR
Sponsor: Jennifer Saultz

Sex: All

Age: 18+

Code: NCT03874052

Phase1, Recruiting

OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study

for
MDS, Myelodysplastic Syndromes,
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre

Sex: All

Age: 18+

Code: NCT06270771

Recruiting

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

for
Juvenile Myelomonocytic Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 0 - 70+

Code: NCT03326921

Phase1, Recruiting

Home Blood Transfusions

for
Hematologic Malignancy, Myelodysplastic Syndromes,
Location: Philadelphia PA
Sponsor: Thomas Jefferson University

Sex: All

Age: 18+

Code: NCT07121140

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

for
Myelodysplastic Syndromes
Location: New Haven CT, Calgary, Toronto, Canton OH, Houston TX,
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06847867

Phase2, Recruiting

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

for
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18+

Code: NCT07046078

Phase2, Recruiting